Alligator Bioscience – Tumor-directed immunotherapy of cancer

23 October – Webinar in connection with Q3 interim report

Alligator will host a webinar and conference call for investors, analysts, and media at 3:00 p.m. CEST / 9:00 a.m. EDT, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the interim report. The presentation will be followed by a Q&A session.

The call will be held in English. Attendees are required to register in advance by following >>this link<<, and are welcome to submit questions in advance to ir@alligatorbioscience.com.

19 August – R&D event

Alligator hosted a virtual R&D Day on Tuesday, 19 August 2025 providing an in-depth update on Alligator’s R&D pipeline, with a primary focus on its lead candidate mitazalimab, ahead of the upcoming TO 13 warrant exercise period (1–15 September 2025).

I would like to see the webinar!